摘要
肾细胞癌(renal cell carcinoma,RCC)是最常见的肾脏肿瘤,其发病率呈逐年上升趋势,近年来随着RCC增殖分子机制研究的深入和新的分子靶向药物不断问世,RCC患者的生存率及生活质量均得到显著提高,RCC的治疗进入了分子靶向时代。更重要是的,多靶点药物舒尼替尼已经取代传统的IFN被列为转移性RCC的一线标准治疗药物,联合分子靶向治疗与免疫治疗将是未来的发展方向。本文就舒尼替尼治疗RCC的研究现状及进展作一综述。
Renal cell cancer（RCC） is the most common form of cancer of the kidney and its annually morbility is still in the tendency to ascend.Recently,molecular mechanisms responsible for the proliferation of RCC are identified,and molecular targeted therapy is developed.Bevacizumab,sorafenib,sunitinib,axitinib and temsirolimus are promising molecular targeted therapeutic agents for metastatic RCC.Above all,sunitinib has replaced IFN as a first-line standard of care in the treatment of metastatic RCC.In addition,combination therapy with molecular targeted therapy and other therapies including immunotherapy may also be developed soon.
出处
《临床肿瘤学杂志》
CAS
2010年第5期461-464,共4页
Chinese Clinical Oncology
关键词
舒尼替尼
肾细胞癌
Sunitinib
Renal cell carcinoma
